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Abstract
Background: In the era of cytokines, patients with brain metastases (BM) from renal cell carcinoma had a
significantly shorter survival than patients without. Targeted agents (TA) have improved the outcome of patients
with metastatic renal cell carcinoma (mRCC) however, their impact on patients with BM is less clear. The aim of
this analysis was to compare the outcome of patients with and without BM in the era of targeted agents.
Methods: Data from 114 consecutive patients who had access to targeted agent were analyzed for response rates
(ORR), progression free survival (PFS) and overall survival (OS). All patients diagnosed with BM underwent local, BM-
specific treatment before initiation of medical treatment.
Results: Data of 114 consecutive patients who had access to at least one type of targeted agents were analyzed.
Twelve out of 114 renal cell carcinoma (RCC) patients (10.5%) were diagnosed with BM. Systemic treatment
consisted of sunitinib, sorafenib, temsirolimus or bevacizumab. The median PFS was 8.7 months (95% CI 5.1 - 12.3)
and 11.4 months (95% CI 8.7 - 14.1) for BM-patients and non-BM-patients, respectively (p = 0.232). The median
overall survival for patients with and without BM was 13.4 (95% CI 1- 43.9) and 33.3 months (95% CI 18.6 - 47.0) (p
= 0.358), respectively. No patient died from cerebral disease progression. ECOG Performance status and the time
from primary tumor to metastases (TDM) were independent risk factors for short survival (HR 2.74, p = 0.001; HR:
0.552, p = 0.034).
Conclusions: Although extracerebral metastases determine the outcome of patients with BM, the benefit from
targeted agents still appears to be limited when compared to patients without BM.
Background
Brain metastases (BMs) are observed in 2% to 17% of
patients with metastatic renal cell carcinoma (mRCC)
[1]. The majority of these patients present with meta-
static disease in multiple organs. Despite the availability
of several local treatment strategies for BMs, such as
conventional surgery, whole brain radiation therapy
(WBRT) and stereotactic radiation (SR), the prognosis
of these patients is poor. Patients with BMs were
reported to have a median overall survival of 4-5
months after diagnosis and treatment of cerebral lesions
[2].
Upon diagnosis of BM, patients usually undergo neu-
rosurgical and/or radiotherapeutic procedures whereas
medical treatment may be offered later. The choice for a
specific type of local treatment depends on the size and
number of BMs, their intracerebral location and the
patient’s condition. Historical data have shown that
stereotactic radiation for BMs from renal cell carcinoma
(RCC) may result in brain-specific disease control up to
10 months [3,4]. Another effective local treatment
option is surgery. Most brain metastases from renal cell
carcinoma (RCC) are well circumscribed and relatively
firm, which makes them suitable for complete surgical
resection. Surgical resection was shown to enable a
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contrast, whole brain radiation appears to confer the
smallest benefit in terms of median time to local disease
progression (3 to 8 months) [5].
Although surgery or stereotactic radiation may be
highly effective to reduce the risk of brain-specific dis-
ease progression, BM-patients were shown to have a
shorter survival than patients without BM [6]. Interest-
i n g l y ,s e v e r a la u t h o r so b s e r v e dt h a tt h i sw a sr e l a t e dt o
the lack of effective medical treatment options with
rapid extracerebral disease progression rather than to
BM-associated complications such as bleeding or
increased brain pressure [1,2,5,7]. BM-patients were
mostly considered unsuitable for cytokines and only few
reports indicate that interferon-alpha (IFN-alpha) and/or
interleukin-2 (IL-2) following local BM-treatment may
confer survival benefits [7]. These observations suggest
that effective medical treatment may account for the
outcome of BM-patients rather than the diagnosis of
BMs per se.
Therapeutic options for mRCC have tremendously
improved in the last 3 years [8-11]. When compared to
interferon-alpha, first-line treatment with the tyrosine
kinase inhibitor (TKI) sunitinib was shown to signifi-
cantly improve objective remission rates (39% versus
12%), progression free survival (11 months versus 5
months) and overall survival (26.4 months versus 21.8
months) [12]. Similarly, first-line treatment with the
monoclonal antibody bevacizumab in combination with
interferon-alpha was shown to provide a statistically sig-
nificant benefit in overall response rate (ORR) (31% ver-
sus 13%) and PFS (10.2 months versus 5.4 months) [11]
when compared to IFN-alpha alone. In poor risk
patients, treatment with the mammalian target of rapa-
mycin (mTOR)-inhibitor temsirolimus was associated
with a statistically significant benefit in OS when com-
pared to patients treated with IFN-alpha (10.9 months
versus 7.3 months) [10]. In second-line, the tyrosine
kinase inhibitor sorafenib was shown to double PFS (5.5
versus 2.8 months, HR: 0.44, 95%CI 0.35-0.55, p < 0.01)
when compared to placebo in patients who had pro-
gressed on cytokine treatment [9]. Finally, the oral
mTOR inhibitor everolimus was shown to reduce the
risk for progression in patients who had failed Vascular
endothelial growth factor receptor (VEGFR)-based TKI
first-line treatment (HR 0.30, 95%CI: 0.22-0.40) [13].
Patients with BM were excluded from these pivotal
trials, however, subsequently initiated smaller studies
also investigated the outcome of BM-patients and sev-
eral authors have shown that sunitinib and sorafenib
can be given safely, i.e. without haemorrhage in patients
with BMs [6,14-18].
With the advent of these novel agents, extracerebral
disease control is enabled in the majority of patients. As
patients with BM are endangered by distant metastases
rather than brain metastases, we hypothesized that
response rates, progression-free survival and overall sur-
vival should be similar in patients with and without BM.
The aim of this retrospective analysis was to compare
the outcome of patients with and without BM since the
start of the era of targeted agents and to investigate
whether progression of brain metastases is the most lim-
iting factor for overall survival.
Methods
All patient data were collected at the Department of
Medicine I and Cancer Center, Clinical Division of
Oncology at the Medical University of Vienna. This ret-
rospective analysis was performed in accordance with
the ethical regulations of the Medical University of
Vienna.
Patients
Data from 114 consecutive mRCC patients who had
access to at least one type of targeted agent during their
course of the disease were recorded and analyzed for pre-
s e n c eo fB Ma tt h es t a r to ft h ef i r s tt a r g e t e da g e n t ,
response to treatment, progression free survival, overall
survival and cause of death. The first novel agent pro-
vided and reimbursed was bevacizumab, which was avail-
able for off label use in October 2005. Sunitinib,
sorafenib, temsirolimus were available later, i.e. in Febru-
ary 2006, June 2006 and March 2007, respectively. The
choice for a specific medical treatment was first based on
the availability of these agents and later on the results of
the pivotal trials. Sunitinib and sorafenib were prescribed
at a daily dose of 50 mg (on a 4 weeks on, 2 weeks off
schedule) and 800 mg/d (continuously), respectively.
Temsirolimus was prescribed at a weekly dose of 25 mg
and bevacizumab every 2 weeks at 10 mg/kg body weight.
Staging investigations were performed at baseline and
every 3 months and earlier if clinically required. Response
to treatment was evaluated according to the Response
Criteria in Solid Tumors (RECIST) [19]. The diagnosis of
BMs was made by computed tomography (CT) scan or
magnet resonance tomography (MRI).
Statistical methods
O Sw a sc a l c u l a t e df r o mt h es t a r to ft h ef i r s tt a r g e t e d
therapy until death. Survival was calculated using the
Kaplan-Meier method and groups (no brain metastases
versus brain metastases at start of first targeted agent)
were compared with the log-rank test. Patient character-
istics were compared between the different groups by
using the Chi-Square test and the Fisher’sE x a c tt e s t .
Multivariate analyses were performed with Cox-Regres-
sion. A two-sided p-value lower or equal 0.05 represents
significance in all tests.
Vogl et al. BMC Cancer 2010, 10:480
http://www.biomedcentral.com/1471-2407/10/480
Page 2 of 10Results
Patient characteristics are outlined in table 1. Between
October 2005 and February 2009, 114 consecutive
patients with a median age of 65.5 years (range 45-88
years) had access to at least one targeted agent during
their course of the disease. The majority of the patients
were in good performance status (ECOG 0: 72.8%) and
were intermediate risk (58.7%) according to the Memor-
ial Sloan-Kettering Cancer Center (MSKCC) criteria
[20]. The most common site of metastases was the lung
(69.3%) followed by bone (36%) and lymph nodes
(33.3%). 47.4% of the patients had 2 metastatic sites. All
but 6 patients had undergone nephrectomy. Sixty-five
out of 114 patients (57%) had prior therapies for meta-
static disease consisting of cytokines and/or chemother-
apy, another forty-nine patients (43%) were treatment
naïve. The first targeted agents were mostly sunitinib
(63.2%) and sorafenib (30.7%). Another 4 and 3 patients
received bevacizumab and temsirolimus as the first tar-
geted agent. Twelve out of 114 patients (10.5%) had - in
addition to extracerebral metastases- BM at baseline and
underwent local treatment before targeted agents were
offered.
Specific characteristics of BM patients at diagnosis of
brain metastases
Specific characteristics of BM patients are shown in
Table 2. The median age of BM patients was 66 years.
All BM-patients had extracerebral metastases (clear cell
n= 2, non clear-cell n = 10), 41.7% in 2 or more other
sites. The most common sites were the lung (67%) and
lymph nodes (25%). Six patients (50%) had 2 or more
cerebral lesions. Brain metastases were mostly located in
the cerebellum (33.3%) or the frontal lobe (33.3%). In
75% of BM patients, at least one lesion was larger than
2 cm. The majority of BM-patients (83%) were sympto-
matic at diagnosis of BM, the most common symptoms
being headache and ataxia. All patients diagnosed with
BMs underwent local treatment (surgery only: n = 2;
stereotactic radiation only: n = 2; whole brain radiation
only n = 3, combinations: n = 5).
Response to Treatment, Progression Free Survival and
Overall Survival
As outlined in table 3, 33 out of 109 evaluable patients
(30.3%) achieved objective remission under their first
targeted agent (complete remission (CR): n = 6, partial
remission (PR): n = 27). Another 61 patients (56%)
achieved stable disease (SD) for more than 3 months.
Three out of 12 BM-patients (25%) achieved objective
remission (CR: n = 1, PR: n = 2). Another seven patients
Table 1 Baseline characteristics of renal cell carcinoma
patients (n = 114)
Characteristics N %
Sex
male 69 60.5
female 45 39.5
Age
median (range) 65.5 (45-88) 47.4
< 65 54 52.6
>6 5 6 0
ECOG
0 83 72.8
1 28 24.6
2 3 2.6
Nephrectomy
Yes 108 94.7
no 6 5.3
Time from primary to metastasis
< 1 year 56 49.1
> 1 year 58 50.9
Histology
clear cell 104 91.2
non clear cell 10 8.8
MSKCC
favourable 45 39.5
intermediate 67 58.7
poor 2 1.8
Number of metastasis
1 32 28.1
2 54 47.4
> 3 28 24.5
Location of metastasis
Lung 79 69.3
Liver 22 19.3
Bone 41 36
Lymph nodes (LN) 38 33.3
CNS 12 10.5
other 41 36
Systemic therapy before first Targeted Agent
(TA)
Cytokines 54 47.4
other 11 9.6
First targeted agent
Bevacizumab 4 3.5
Sunitinib 72 63.2
Sorafenib 35 30.7
Temsirolimus 3 2.6
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Age (median, range) 66 (45-88)
n%
Number of extracerebral metastatic sites at occurrence of BM
-1 7 58.3
-2 2 16.7
- ≥ 3
Location of extracerebral metastases
Lung 8 66.7
Liver 2 16.7
Bone 2 16.7
LN 32 5
other 5 41.7
Time from primary tumor to occurrence of BM
< 2 years 97 5
> 2 years 32 5
Number of brain lesions
1 65 0
2 4 33.3
>2 2 16.7
Location of BM metastases
- frontal 4 33.3
- parietal 2 16.7
- cerebellar 4 33.3
- temporal 1 8.3
- dissiminated 1 8.3
Lesion size
1cm 1 8.3
1-2cm 2 16.7
> 2cm 97 5
CNS symptoms
Yes 10 83.3
No 2 16.7
- psychiatric 1 8.3
- vertigo 2 16.7
- headache 5 41.7
- ataxia 3 25
- hemiplegia 1 8.3
Local treatment for BM
- surgery 2 16.7
- surgery+ SR 1 8.3
- surgery+WBRT 2 16.7
-S R 2 16.7
- SR+WBRT 2 16.7
- WBRT 3 25
First targeted agent after local control of BM
- Bevacizumab 2 16.7
- Sunitinib 7 58.3
- Sorafenib 2 16.7
- Temsirolimus 1 8.3
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Page 4 of 10(58.3%) had SD for at least 3 months. The PFS was 10.9
months (range 8.3-13.5), 11.4 months (8.7-14.1) and 8.7
(5.1-12.3) for the entire population, non-BM-patients
and BM-patients, respectively (p = 0.232) (Figure 1).
The median overall surviva lw a s3 3 . 3m o n t h s( 9 5 % C I :
19.3-47.2), 33.3 months (95%CI: 18.6-47.9) and 13.4
months (95%CI: 1-43.9) for the entire population, for
non-BM and BM patients, respectively (p = 0.358) (Fig-
ure 2).
The individual course of disease of BM-patients is
outlined in table 4. Three out of 12 BM-patients had a
central nervous system (CNS)-relapse and underwent
Figure 1 Progression free survival of 114 patients with and without BM. Median PFS: 10.9 months (95%Ci: 8.3-13.5), 11.4 months (95% CI:
8.7-14.1) and 8.7 (95% CI: 5.1-12.3) for the entire population, non-BM-patients and BM-patients, respectively (p = 0.232).
Table 3 Outcome of renal cell carcinoma patients with and without cerebral metastasis
All patients
n = 109
n
% Patients without
BM
n=9 7
n
% Patients with BM
n=1 2
n
%
Best response to TA
- CR 6 5.5 5 5.2 1 8.3
- PR 27 24.8 25 25.8 2 16.7
- SD 61 56 54 55.7 7 58.3
- PD 15 13.8 13 13,4 2 16.7
All patients
n = 114
median
(months)
95%CI Patients without
BM
n= 102 median
(months)
95% CI Patients with BM n = 12
median (months)
95% CI
Progression free survival (start first
TA- progression)
10.9 8.3-13.5 11.4 8.7-14.1 8.7 5.1-12.3
Overall survival (start first TA- death) 33.3 19.3-47.2 33.3 18.6-47.9 13.4 1-43.9
BM = brain metastases
TA = targeted agent
CR = complete response
PR = partial response
SD = stable disease
PD = progressive disease
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been diagnosed with or died from BM-specific disease
progression since local treatment. ECOG Performance
status and the time from primary tumor to metastases
were independent risk factors for short survival while no
patients died from cerebral disease progression (ECOG
Performance status 0: 42 months 95%CI: 19.33-47.2,
ECOG >1: 16.4 months, 95%CI: 10.3-22.5, Hazard ratio
(HR 2.74, p = 0.001), TDM <1 year: 20.6 months, 95%
CI: 14.1-27.1, and TDM >1 year: 42 months, 95%CI
32.8-51.2, HR: 0.552, p = 0.034).
CNS-related PFS and BM recurrence
The median CNS-related PFS (start of local BM-treat-
ment to BM recurrence) is 12.37 months (95% CI: 1-
49.76). Three out of 12 patients (25%) had a BM recur-
rence. Two patients had a progression in lesion size
after local treatment and one patient had a relapse of
the resected metastasis and new CNS lesions.
Toxicity and treatment-related side effects of BM and
non-BM patients
The most common grade 3 and 4 toxicities in BM-
patients were diarrhoea (22.2%), nausea (11.1%) and
hypertension (11.1%). In non-BM patients hypertension
(19.6%), hand/foot-syndrome (17.6%) and diarrhoea
(12.8%) were the most common grade 3 and 4 toxicities.
Discussion
In the era of cytokine treatment, extracerebral metas-
tases rather than brain metastases were shown to deter-
mine the course of disease in patients with advanced
RCC and brain lesions. Most patients with BM either
did not benefit from cytokine treatment or were consid-
ered unsuitable for cytokines [21]. The advent of tar-
geted agents for RCC has enabled significantly better
control of systemic disease [8-11, 13]. Thus we hypothe-
sized that patients with and without BM may have simi-
lar benefits from modern agents. We found that
targeted agents led to quite similar response rates in
patients with and without BM. However, the median
progression free survival and overall survival were strik-
ingly lower in patients with BM when compared to
patients without (PFS: 8.7 versus 11.4 months, p =
0.232, OS: 13.4 months versus 33.3 months, p = 0.358).
A limitation of our report is the variety of local and sys-
temic therapies offered (i.e. stereotactic radiosurgery or
WBRT, sunitinib, sorafenib, bevacizumab and temsiroli-
mus). Moreover, differences in PFS and OS did not
reach statistical significance due to the small number of
patients. However, our findings are consistent with
other reports. In the sunitinib extended access program,
the median progression free survival and overall survival
for the entire population were 10.9 and 18.4 months,
respectively, whereas the subgroup of patients with BM
Figure 2 Overall survival of 114 patients with and without BM. Median OS: 33.3 months (95%CI: 19.3-47.2), 33.3 months (95%CI: 18.6-47.9)
and 13.4 months (95%CI: 1-43.9) for the entire population, for non-BM and BM patients, respectively (p = 0.358).
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Patient MSKCC
risk
group
ECOG
performance
status at
diagnosis of
BM
Extracerebral
metastatic
site
TX prior
first TA
Time from
primary
metastasis
to BM
(months)
BM-
TX
CNS
recurrence
during/after
TA
First
TA
Best
Response
PFS Following
TX lines
OS Progressing
metastatic
site leading
to death
1 fav 0 Lung Cytokines 0 surg no SU CR 24.2 Ongoing 24.2 non
progressing
and alive
2 interm 0 Lung Cytokines,
Capecitabin
45 surg no Beva SD 8.7 SU
Soraf
Tems
Tems+Beva
46.9 non
progressing
and alive
3 interm 1 lung, LN no 0 surg,
WBRT
no SU SD 8.5 ongoing 8.5 non
progressing
and alive
4 interm 1 lung, other Cytokines 72 SR no Beva SD 21.6 SU, Tems 36.9 lung, liver
5 fav 0 liver, bone,
other
Cytokines,
Navelbine
27 WBRT,
SR
yes
(progression
in lesion
size)
Soraf PD 2.6 SU 13.42 lung.
6 interm 1 other no 0 SR,
WBRT
yes
(progression
in lesion
size)
SU PD 3.4 Tems, Beva
+Interferon
10.16 Liver
7 interm 0 Ln no 0 WBRT no SU PR 3.26 Soraf 18.82 non
progressing
and alive
8 interm 1 lung no 0 Surg,
SR
no SU SD 12.1 SU 40.6 non
progressing
and alive
9 interm 1 lung, liver,
other
no 0 SR no Tems SD 6.3 no 6.3 liver, lung
10 interm 0 lung, ln no 8 WBRT no Soraf PR 10.9 no 10.9 Lung
11 interm 0 lung, other Cytokines,
Navelbine
14 Surg,
WBRT
yes (relapse
of resected
lesion and
new lesions)
SU SD 3.8 no 3.8 cranial
vertebral
fractures
12 poor 2 bone no 0 WBRT No SU SD 6.7 no 6.7 Lung
MSKCC = Memorial Sloan-Kettering Center Center
fav = favourable risk
interm = intermediate risk
poor = poor risk
ECOG = Eastern Cooperative Oncology Group
TX = treatment
TA = targeted agent
BM = brain metastasis
SR = stereotactic radiation
WBRT = whole brain radiation therapy
Surg = surgery
SU = Sunitinib
Soraf = Sorafenib
Tems = Temsirolimus
Beva = Bevacizumab
CR = complete remission
PR = partial remission
SD = stable disease
PD = progressive disease
PFS = progression free survival
OS = overall survival
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9.2 months, only [6].
Although (radio-) surgery was shown to provide excel-
lent local control in up to 96% of the patients [1,22], it
w o u l db ee x p e c t e dt h a tr e d u c e do v e r a l ls u r v i v a lo fB M -
patients is related to the tenuous site of metastases. This
is supported by the report of Sperduto and colleagues
who found that the number of cerebral lesions is an
independent prognostic factor in patients with RCC
[23]. Brain metastases may dramatically endanger the
patient by leading to local edema, increased intracranial
pressure and fatal bleeding. However, in our series,
brain metastases per se were not responsible for shorter
survival of these patients. All patients with BMs were
neurologically unsuspicious in the last 24 hours before
death and died obviously from disease progression of
extracerebral metastatic sites, leading most commonly
to respiratory or hepatic failure. Among those who are
alive, none is endangered by intracerebral disease pro-
gression. Hence, the presence of BM was not a risk fac-
tor for shorter overall survival (p = 0.358). In the
multivariate analysis, only ECOG Performance status
(ECOG 0: 42 months 95%CI: 19.33-47.2, ECOG >1:16.4
months, 95%CI: 10.3.22.5, HR: 2.74, p = 0.001) and the
time from primary tumor to development of metastases
(< 1 year: 20.6 months, 95%CI 14.1-27.1, and > 1 year:
42 months, 95%CI 32.8-51.2, HR: 0.552, p = 0.034) were
independent risk factors for short survival. Our results
are consistent with the findings of Hara et al. who
reported that a poor performance status accounts for
shorter survival of BM-patients rather than the presence
of brain metastases per se [22]. Consequently the
authors suggested that effective therapeutic strategies
for systemic disease may prolong survival in patients
with locally treated brain metastases.
Although all patients of the present analysis had
access to at least one type of effective RCC treatment
leading to stable disease or objective remission in the
majority and while no patient died from BM-related
progression, the outcome is still different between BM
and non-BM-patients. Several reasons may account for
these differences. First, brain metastases were shown to
occur late in the progression of mRCC [24]. Conse-
quently, the overall survival of these patients may often
reflect only the length of the very last life span within
the course of metastatic disease. Second, the occurrence
of brain metastases may represent an epiphenomenon of
an altered, meanwhile highly aggressive behaviour of the
tumor. Hence, it could be speculated that patients with
BM require far more aggressive treatment strategies
than patients without and that alternative therapeutic
targets may become more relevant. In this context, the
signal transducer and activator of transcription 3 (Stat3)
might be an interesting target. Activation of Stat3 was
shown to be increased in brain metastases [25]. Suniti-
nib inhibits Stat3 in both tumor cells and tumor mye-
loid cells [26], thereby leading to tumor cell apoptosis
and reduced expression of angiogenic genes and immu-
nosuppressive cells. However, persistent Stat3 activation
has been shown to rescue tumor cells from sunitinib-
induced cell death [26] and to promote cell proliferation
by regulating genes encoding antiapoptotic and prolif-
eration-associated proteins [27]. Patients with brain
metastases and activated Stat3 may require a treatment
strategy that inhibits Stat3 in various ways. A combina-
tion of sunitinib with an anti-interleukin-6 antibody has
been suggested, since Stat3-activation is mediated by the
interleukin-6 receptor [26]. Another promising target
whose expression correlates with advanced stage of dis-
ease is the chemokine receptor CXCR4, a key receptor
in the crosstalk between tumor cells and their environ-
ment [28]. In RCC, the loss of function of the Von Hip-
pel Lindau (VHL) tumor supressor gene mediates up-
regulation of CXCR4 [29] which then promotes tumor
spread and progression [28]. The activity of CXCR4-
directed agents has already been shown in animal tumor
models [30] and might be of particular interest in
rapidly progressing tumors.
Conclusions
Despite both excellent neuro(radio-)surgical strategies
and advances in the treatment of systemic mRCC, the
course of disease of patients with brain metastases
remains an enormous challenge. These patients are
endangered by rapidly progressing extracerebral metas-
tases rather than progressing brain metastases. Thus,
different i.e. more complex therapeutic concepts are
urgently required for this patient population and base-
line and repeated CT-scans of the brain should be pro-
vided in all patients in order to enable highly potent
local treatment options.
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